hVIVO (HVO) Share Price, News & Analysis

Company Overview

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: 21.70 to 23.40
• 50-Day Range: 23.80 to 29.80
• 52-Week Range: 16.76 to 32
• Volume: 3.91 million shs
• Average Volume: 3.54 million shs
• Market Capitalization: £156.14 million
• P/E Ratio: 765.00
• Dividend Yield: 0.73%
• Price Target: N/A
• Consensus Rating: N/A

HVO Stock Analysis - Frequently Asked Questions

How have HVO shares performed this year?

hVIVO's stock was trading at GBX 23.75 at the beginning of 2024. Since then, HVO shares have decreased by 2.8% and is now trading at GBX 23.09.
View the best growth stocks for 2024 here.

How were hVIVO's earnings last quarter?

hVIVO plc (LON:HVO) announced its quarterly earnings data on Thursday, April, 19th. The company reported ($16.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($10.90) by $5.60. hVIVO had a trailing twelve-month return on equity of 58.04% and a net margin of 25.96%.

How do I buy shares of hVIVO?

Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of hVIVO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR).

Company Calendar

• Last Earnings: 4/19/2018
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:HVO
• Previous Symbol: LON:RVG
• CUSIP: N/A
• CIK: N/A
• Web: hvivo.com
• Phone: +44-20-77561300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.03
• Trailing P/E Ratio: 766.67
• Forward P/E Ratio: 14.85
• P/E Growth: N/A
• Net Income: £17.45 million
• Net Margins: 25.96%
• Pretax Margin: N/A
• Return on Equity: 58.04%
• Return on Assets: 11.97%

Debt

• Debt-to-Equity Ratio: 33.86
• Current Ratio: 1.61
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: £67.21 million
• Price / Sales: 2.33
• Cash Flow: GBX 4.66 per share
• Price / Cash Flow: 4.94
• Book Value: GBX 6 per share
• Price / Book: 3.83

Miscellaneous

• Outstanding Shares: 680,370,000
• Free Float: N/A
• Market Cap: £156.49 million
• Optionable: Not Optionable
• Beta: 0.97